Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer

被引:2
|
作者
Azzouzi, Abdel-Rahmene
Larre, Stephane
Cormier, Luc
Roupret, Morgan
Valeri, Antoine
Mangin, Philippe
Berthon, Philippe
Villette, Jean-Marie
Fiet, Jean
Cussenot, Olivier
机构
[1] CHU Angers, Dept Urol, F-49933 Angers, France
[2] CeRePP, UPRES, UFR, Biomed St Peres, Paris, France
[3] CHU Nancy Brabois, Dept Urol, Vandoeuvre Les Nancy, France
[4] CHU Cavale Blanche, Brest, France
[5] UroGene, Evry, France
[6] Hop St Louis, Dept Hormonol, Paris, France
[7] Inst Univ France, Paris, France
关键词
PSA; mass screening; prostate cancer; population surveillance;
D O I
10.1111/j.1464-410X.2006.06701.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To assess the reliability of a new measurement of prostate-specific antigen (PSA) using a blotting-paper assay (nanotest) compared to the standard PSA immunoassay. SUBJECTS AND METHODS: The PSA level was measured in 205 men volunteers (median age 70 years, range 41-75) using a nanotest and a standard PSA immunoassay, collected at the same time; 30 mu L of capillary blood placed on to a blotting paper were collected for the nanotest and sent by mail to the same laboratory for the two assays. The results were compared statistically using the Spearman test, the intraclass correlation coefficient and the Bland-Altman test. RESULTS: The nanotest threshold for an abnormal PSA level was 78 pg/mL, which corresponded to a standard PSA value of 3 ng/mL, with a sensitivity of 100%. There was a significant correlation (r = 0.98, Spearman test; P < 0.001) between the nanotest and the standard PSA assay. The intraclass correlation coefficient was 0.87. The Bland-Altman test showed a good agreement between the nanotest and the standard PSA assay, but there was an increasing proportional difference with increasing PSA value. CONCLUSION: There was a very high correlation between the nanotest and the standard PSA assay, especially for standard PSA levels of < 5 ng/mL. Economic and clinical studies are indicated to confirm the utility of the nanotest in organized mass screening of prostate cancer.
引用
收藏
页码:762 / 764
页数:3
相关论文
共 50 条
  • [31] Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation
    Schaefer, U
    Witt, F
    Schueller, P
    Micke, O
    Willich, N
    ANTICANCER RESEARCH, 2000, 20 (6D) : 4989 - 4992
  • [32] Heterogeneity in prostate cancer: Prostate specific antigen (PSA) and DNA cytophotometry
    Krause, FS
    Feil, G
    Bichler, KH
    Schrott, KM
    Akcetin, ZY
    Engehausen, DG
    ANTICANCER RESEARCH, 2005, 25 (3A) : 1783 - 1785
  • [33] The Clinical Predictors of Malignancy in the Prostate Gland and Their Correlation With Prostate-Specific Antigen (PSA) Levels
    Mishra, Aparna
    Mahto, Sunil Kumar
    Paswan, Manoj K.
    Patra, Satyabrata
    Kashyap, Aditi
    Ashu, Tripti
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [34] PSA screening for prostate cancer
    Sadi, Marcus V.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (08): : 722 - 725
  • [35] The validity of rapid test to detect prostate-specific antigen (PSA) in seminal fluid
    Henky
    Budiningsih, Yuli
    Widiatmaka, Wibisana
    MEDICAL JOURNAL OF INDONESIA, 2011, 20 (04) : 278 - 282
  • [36] Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada
    Beaulac, Jennifer A.
    Fry, Richard N.
    Onysko, Jay
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2006, 97 (03): : 171 - 176
  • [37] Percent Free Prostate-Specific Antigen (PSA) Is an Accurate Predictor of Prostate Cancer Risk in Men With Serum PSA 2.5 ng/mL and Lower
    Waiz, Jochen
    Haese, Alexander
    Scattoni, Vincenzo
    Steuber, Thomas
    Chun, Felix K. H.
    Briganti, Alberto
    Montorsi, Francesco
    Graefen, Markus
    Huland, Hartwig
    Karakiewicz, Pierre I.
    CANCER, 2008, 113 (10) : 2695 - 2703
  • [38] Prostate-specific Antigen Testing and Prostate Cancer Screening
    Djavan, Bob
    Eckersberger, Elisabeth
    Finkelstein, Julia
    Sadri, Helen
    Taneja, Samir S.
    Lepor, Herbert
    PRIMARY CARE, 2010, 37 (03): : 441 - +
  • [39] Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
    Cho, Hyungseok
    Oh, Cheol Kyu
    Cha, Jiwon
    Chung, Jae Il
    Byun, Seok-Soo
    Hong, Sung Kyu
    Chung, Jae-Seung
    Han, Ki-Ho
    PROSTATE INTERNATIONAL, 2022, 10 (01) : 14 - 20
  • [40] A "PSA Pyramid'' for Men with Initial Prostate-specific Antigen ≤3 ng/ml: A Plea for Individualized Prostate Cancer Screening
    Randazzo, Marco
    Beatrice, Josef
    Huber, Andreas
    Grobholz, Rainer
    Manka, Lukas
    Chun, Felix K.
    Recker, Franz
    Kwiatkowski, Maciej
    EUROPEAN UROLOGY, 2015, 68 (04) : 591 - 597